Christina Paitazoglou works in Heart Failure / Cardiomyopathy affiliated with University Hospital Schleswig-Holstein.
PD Dr. med. Christina Paitazoglou is Oberärztin and head of the Heart Failure Unit and cardiological outpatient clinic at Medizinische Klinik II of Universitätsklinikum Schleswig-Holstein (UKSH) Campus Lübeck / University Heart Center Lübeck. She is an interventional cardiologist who has contributed to clinical trials including the PRELIEVE study of the Atrial Flow Regulator in heart failure patients. She is also listed as an interventional cardiologist at Cardiologicum Hamburg Wandsbek practice.
42 pubs · 782 cites · h-index 13
Oberärztin, Leitung Heart Failure Unit und kardiologische Ambulanz
Universitätsklinikum Schleswig-Holstein (UKSH), Campus Lübeck / University Heart Center Lübeck
Interventional cardiologist / Cardiologist
Cardiologicum Hamburg - Wandsbek practice
Interventional / Structural Cardiology · Twitter (United States)
Almost three-fourths of all the DRTs happened beyond the 45 days, which is when we currently tell patients they can stop the blood thinner, based on the [indications for use].... So the fact that DRT happens late remains concerning.
Journal of the American College of CardiologySimard et al.
ESC Heart FailureBakhshaliyev et al.cohort
In heart failure patients undergoing Atrial Flow Regulator interatrial shunting, impaired baseline RV–PA coupling (lower TAPSE/PASP ratio) is associated with higher rates of cardiovascular death and recurrent heart failure hospitalizations, highlighting its potential utility for patient selection.
Zippel‐Schultz et al.cohort
Supports HF network care for stable HRQoL; leaves open comparative efficacy versus usual care in randomized trials.
Cardiologist · University Medical Center Göttingen-Georg August University
The results of the interim analysis at the prespecified 3-month time point support further investigation of heart remuscularization with BioVAT in patients with advanced stage C or D heart failure that is resistant to guideline-directed medical therapy.
New England Journal of MedicineZimmermann et al.
American Heart JournalSaraei et al.RCT
OAC safety and efficacy remain uncertain in AF with kidney failure; dedicated LAA closure RCT leaves open nonpharmacologic alternative pending results.
Interventional / Structural Cardiology · Universität Hamburg
Taking all this information together, we believe that it is likely that decreased phosphorylation of myofilament proteins – which may be caused by some kind of disturbance in calcium metabolism – may partially account for the impaired contractility and shortened systolic period seen in Takotsubo syndrome.
Journal of the American College of CardiologyStiermaier et al.
ESC Heart FailurePaitazoglou et al.cohort
Implementing a regional, multi-sectoral heart failure network with shared standard operating procedures doubled outpatient HF care utilization and increased specialist referrals, though early reductions in rehospitalization rates did not reach statistical significance.
European Journal of Heart FailureKarakas et al.RCT
Intravenous ferric carboxymaltose significantly reduced cardiovascular death and heart failure hospitalizations in men with heart failure and iron deficiency, but women did not derive similar benefits and may have an increased mortality risk.
Atherosclerosis PlusMezger et al.cohort
Routine Lp(a) measurement is rarely performed in patients with acute myocardial infarction, and retrospective analysis shows no correlation between Lp(a) levels and surrogate markers of heart failure (EF and NT-proBNP) in this cohort.
European Journal of Heart FailureAnker et al.RCT
Provides updated RCT evidence on IV ferric carboxymaltose in HFrEF with iron deficiency; extends prior trials to contemporary GDMT including SGLT2 inhibitors.
A growing body of randomized clinical trials demonstrates that treating ID, particularly with intravenous iron, improves symptoms, exercise capacity, and quality of life, with emerging evidence for reductions in HF hospitalizations.
JAMAAnker et al.
Catheterization and Cardiovascular InterventionsMezger et al.cohort
Steerable sheath yields comparable LAAC metrics to standard; leaves open any advantage in randomized trials.
JAMA NeurologyMaarse et al.Clinical Trial
Cohort study reveals lower ischemic stroke risk with left atrial appendage occlusion in atrial fibrillation despite anticoagulation, suggesting mechanical closure improves secondary prevention.
European Heart Journal Acute Cardiovascular CareZeymer et al.Cohort Study
Aims The prospective GULLIVE-R study aimed to evaluate adherence to guideline-recommended secondary prevention, physicians’ and patients’ estimation of cardiac risk, and patients’ knowledge about target values of risk factors after acute myocardial infarction (AMI). Methods and results We performed a prospective study enrolling patients 9–12 months after AMI. Guideline-recommended secondary prevention therapies and physicians as well as patients’ estimation about their risk and patients’ knowledge about target values were prospectively collected. Between July 2019 and June 2021, a total of 2509 outpatients were enrolled in 150 German centres 10 months after AMI. The mean age was 66 years, 26.4% were women, 45.3% had ST elevation myocardial infarction, 54.7% had non-ST elevation myocardial infarction, and 93.6% had revascularization (84.0% percutaneous coronary intervention, 7.4% coronary artery bypass graft, 1.8% both). Guideline-recommended secondary drug therapies were prescribed in over 80% of patients, while only about 50% received all five recommended drugs (aspirin, P2Y12 inhibitors, statins, beta-blockers, renin–angiotensin–aldosterone system inhibitors), and regular exercise was performed by only one-third. About 90% of patients felt well informed about secondary prevention, but the correct target value for blood pressure was known in only 37.9% and for LDL-cholesterol in only 8.2%. Both physicians and patients underestimated the objective risk of future AMIs as determined by the thormbolysis in myocardial infarction (TIMI) risk score for secondary prevention. Conclusion There is still room for improvement in patient education and implementation of guideline-recommended non-pharmacological and pharmacological secondary prevention therapies in patients in the chronic phase after AMI.
JACC: Cardiovascular InterventionsAarnink et al.Original Research
BACKGROUND: Left atrial appendage occlusion (LAAO) provides mechanical cardioembolic protection for atrial fibrillation (AF) patients who cannot use oral anticoagulation therapy (OAT). Patients with a thrombotic event despite OAT are at high risk for recurrence and may also benefit from LAAO. OBJECTIVES: This study sought to investigate the efficacy of LAAO in AF patients with a thrombotic event on OAT compared to: 1) LAAO in AF patients with a contraindication for OAT; and 2) historical data. METHODS: The international LAAO after stroke despite oral anticoagulation (STR-OAC LAAO) collaboration included patients who underwent LAAO because of thrombotic events on OAT. This cohort underwent propensity score matching and was compared to the EWOLUTION (Evaluating Real-Life Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology) registry, which represents patients who underwent LAAO because of OAT contraindications. The primary outcome was ischemic stroke. Event rates were compared between cohorts and with historical data without OAT, yielding relative risk reductions based on risk scores. RESULTS: Analysis of 438 matched pairs revealed no significant difference in the ischemic stroke rate between the STR-OAC LAAO and EWOLUTION cohorts (2.5% vs 1.9%; HR: 1.37; 95% CI: 0.72-2.61). STR-OAC LAAO patients exhibited a higher thromboembolic risk (HR: 1.71; 95% CI: 1.04-2.83) but lower bleeding risk (HR: 0.39; 95% CI: 0.18-0.88) compared to EWOLUTION patients. The mortality rate was slightly higher in EWOLUTION (4.3% vs 6.9%; log-rank P = 0.028). Relative risk reductions for ischemic stroke were 70% and 78% in STR-OAC LAAO and EWOLUTION, respectively, compared to historical data without OAT. CONCLUSIONS: LAAO in patients with a thrombotic event on OAT demonstrated comparable stroke rates to the OAT contraindicated population in EWOLUTION. The thromboembolic event rate was higher and the bleeding rate lower, reflecting the intrinsically different risk profile of both populations. Until randomized trials are available, LAAO may be considered in patients with an ischemic event on OAT.
Catheterization and Cardiovascular InterventionsPaitazoglou et al.cohort
After adjustment for baseline differences, women and men undergoing left atrial appendage occlusion have similar long-term safety and efficacy outcomes, despite women having a slightly higher rate of periprocedural pericardial effusion.
ESC Heart FailureLauder et al.cohort
Should not yet change HFpEF practice; leaves open survival benefit versus controls in randomized trials.
Catheterization and Cardiovascular InterventionsFink et al.cohort
Supports LAA closure feasibility in ESRD; leaves open randomized confirmation of efficacy.
European Journal of Heart FailureQayyum et al.RCT
Intramyocardial injection of allogeneic adipose tissue-derived mesenchymal stromal cells was safe but did not improve cardiac function or clinical symptoms in patients with chronic ischaemic HFrEF.
Clinical Research in CardiologyHaag et al.cohort
Poor marker correlation in ADHF warrants multimodal assessment over single measures; leaves open optimal decongestion targets for trials.
